Loading...
•
Dec 31, 2020
Guardant Health Q4 2020 Earnings Report
Guardant Health's revenue increased driven by precision oncology and development services.
Key Takeaways
Guardant Health reported a 25% increase in revenue for the fourth quarter of 2020, reaching $78.3 million. The growth was primarily driven by a 47% increase in clinical testing revenue and a 148% increase in development services revenue. However, the company experienced a net loss of $93.7 million, or $0.94 per share, compared to a net loss of $25.2 million, or $0.27 per share, in the same period of the previous year.
Revenue reached $78.3 million, a 25% increase compared to Q4 2019.
Clinical testing revenue grew by 47% year-over-year.
Development services revenue increased by 148% year-over-year.
Net loss was $93.7 million, or $0.94 per share.
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health expects full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020. Clinical volumes for 2021 are expected to be greater than 90,000 tests, growing at least 42% over 2020.
Positive Outlook
- Full year 2021 revenue expected to be in the range of $360 million to $370 million.
- Revenue growth of 26% to 29% over full year 2020 is anticipated.
- Clinical volumes for 2021 are expected to be greater than 90,000 tests.
- Clinical test volume is expected to grow at least 42% over 2020.